Giuliana Grossi

Dr. Gerald Smetana encourages PCPs to familiarize themselves with the outpatient drug options for managing COVID-19 because of the limited treatment window for administration.

Expert psychiatrist Dr. Timothy Fong explains the complexity of using marijuana as treatment in a primary care setting and shares advice on how to address it with patients.

Maternal-fetal medicine specialist Dr. Michael Aziz shines a light on the leading complications for pregnant patients and why the US has the highest maternal mortality rate.

At Pri-Med West, primary care providers ask Dr. Michael Ziffra and Dr. Shirah Vollmer all the questions they have about treating mental illness and prescribing different classes of drugs.

Dr. Shirah Vollmer and Dr. Michael Ziffra host a Question & Answer Session addressing common inquiries about mental health treatment in the primary care setting.

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.

Amid major national judicial and legislative deliberation on reproductive health care access, the Brigham and Women's and Harvard University expert joins to discuss the clinical matters of abortion.

Expert gynecologist Dr. Deborah Bartz addresses the clinical implications of an abortion ban if Roe v. Wade is overturned.

The azole antifungal treatment was approved by the FDA to reduce the incidence of recurrent vulvovaginal candidiasis, or chronic yeast infection.

The completion of this study concluded the planned clinical development program for nasal nalmefene and the company expects to file a New Drug Application in the second half of 2022.

This episode features a conversation with Dr. Amelle Shillington and Jacob and Ashley Wiley after Shillington diagnosed the extremely rare genetic disease that's afflicted Aislynn Wiley, and only 69 other documented cases worldwide.

Voxelotor is the first and only FDA-approved medication for children with sickle cell disease.

Emergency medicine specialist urges hospitals to add methylnaltrexone to the hospital formulary after promising research shows the treatment's success with opioid-induced constipation.

Investigators assess the connection between PAPP-A MoM and fibroid size in pregnant women.

methylnaltrexone is more effective, less costly, and can even keep some patients out of the hospital after being treated for opioid-induced constipation in the emergency department.

A new method of opioid disposal was proposed by the FDA in an attempt to mitigate unauthorized access to opioids and lessen risk of addiction.

Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients undergoing a bunionectomy.

An overview of the progress in hemophilia treatments and global access to gene therapy.

A new study evaluates the prognostic potential of exercise testing for patients with sickle cell disease.

After 15 years and 18 patents, the new biotechnology developed by Ariste Medical receives FDA approval to assist in healing ventral hernia repair, one of the most common surgeries.

Positive preliminary biomarker data were reported from the first cohort in the phase 1 portion of the trial.

Barriers to sickle cell disease care are identified across multiple levels including individual, family, provider, and socio-environmental levels according to patient perspectives.

In an interview, Karen Kozarsky, CSO of SwanBio discusses the new data being presented at AAN on AAV-based gene therapy candidate SBT101.

At the AAN 2022 Annual Meeting, SwanBio presents new data regarding lead candidate SBT101 for treating adrenomyeloneuropathy, a rare debilitating disease with no approved therapies.

Dr. Rafael Pérez-Figueroa talks about how the pandemic has exacerbated racial inequities on multiple levels saying that people of color have been overrepresented in jobs with high exposure to COVID-19, leading to disproportionate infections and death.

The NaV1.8 inhibitor VX-548 shows promising potential as a non-opioid acute pain treatment.

Late use of steroids among patients with AIN shows now indication of further recovery and poses an additional risk of exposing patients to adverse effects.

Investigators conducted the largest study on SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses.